TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients

0542897 - MBÚ 2022 RIV US eng J - Článek v odborném periodiku
Raková, J. - Truxová, I. - Holicek, P. - Šálek, C. - Hensler, M. - Kašíková, L. - Pasulka, J. - Holubová, M. - Kovář, Marek - Lysák, D. - Kline, J. P. - Ráčil, Z. - Galluzzi, L. - Spíšek, R. - Fučíková, J.
TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients.
Oncoimmunology. Roč. 10, č. 1 (2021), č. článku 1889822. ISSN 2162-402X. E-ISSN 2162-402X
Institucionální podpora: RVO:61388971
Klíčová slova: Co-inhibitory receptor * innate lymphoid cells * lag-3 * tigit * vista
Obor OECD: Microbiology
Impakt faktor: 7.723, rok: 2021
Způsob publikování: Open access
https://www.tandfonline.com/doi/full/10.1080/2162402X.2021.1889822

Accumulating evidence indicates that immune checkpoint inhibitors (ICIs) can restore CD8(+) cytotoxic T lymphocyte (CTL) functions in preclinical models of acute myeloid leukemia (AML). However, ICIs targeting programmed cell death 1 (PDCD1, best known as PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA4) have limited clinical efficacy in patients with AML. Natural killer (NK) cells are central players in AML-targeting immune responses. However, little is known on the relationship between co-inhibitory receptors expressed by NK cells and the ability of the latter to control AML. Here, we show that hepatitis A virus cellular receptor 2 (HAVCR2, best known as TIM-3) is highly expressed by NK cells from AML patients, correlating with improved functional licensing and superior effector functions. Altogether, our data indicate that NK cell frequency as well as TIM-3 expression levels constitute prognostically relevant biomarkers of active immunity against AML.
Trvalý link: http://hdl.handle.net/11104/0320233